Биология ва тиббиёт муаммолари 2025 №5 (165)

Тема статьи

АЛГОРИТМ ТЕРАПИИ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ (369-374)

Авторы

Саитазизов Хуршид Башруллаевич, Акилов Хабибулла Атауллаевич, Хамраева Гулчехра Шахабовна, Хурсанов Ёкуб Эркин угли

Учреждение

1 - Центр развития профессиональной квалификации медицинских работников, Республика Узбекистан, г. Ташкент; 2 – Самаркандский государственный медицинский университет, Республика Узбекистан, г. Самарканд

Аннотация

В статье представлен современный обзор алгоритмов терапии лёгочной гипертензии, основанный на анализе последних публикаций и клинических рекомендаций. Рассмотрены подходы к ранней диагностике заболевания, включая эхокардиографию, катетеризацию сердца и оценку биомаркеров сердеч-ной нагрузки. Основное внимание уделено индивидуали-зации терапии с использованием комбинированных схем фармакологического лечения, включающих анта-гонисты рецепторов эндотелина, ингибиторы фосфо-диэстеразы-5, стимуляторы гуанилатциклазы и пре-параты простагландинового ряда. Отмечена роль междисциплинарного ведения пациентов, интеграции реабилитационных методов, интервенционных подхо-дов и цифровых технологий мониторинга. Подчерки-вается важность персонализированного подхода и динамической коррекции терапии для улучшения гемо-динамических показателей, качества жизни и долго-срочной выживаемости пациентов.

Ключевые слова

Лёгочная гипертензия, алгоритм терапии, комбинированная фармакологическая терапия, ранняя диагностика, персонализированный подход.

Литературы

1. McLaughlin VV, Rich S. Pulmonary hypertension–advances in medical and surgical interventions. J Heart Lung Transplant. 1998;17(8): 739-743. 2. Galie` N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4): 394-403. 3. Bai Y, Sun L, Hu S, Wei Y. Combination therapy in pulmonary arterial hypertension: a metaanalysis. Cardiology. 2011;120(3):157-165. 4. Galie` N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl): D60–D72. 5. Jaı¨s X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012;40(4):881-885. 6. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114(14):1482-1489. 7. de Man FS, Handoko ML, Groepenhoff H, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;34(3):669-675. 8. Gru¨nig E, Ehlken N, Ghofrani A, et al. Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. Respiration. 2011; 81(5):394-401. 9. Gru¨nig E, Maier F, Ehlken N, et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther. 2012;14(3):R148. 10. Gru¨nig E, Lichtblau M, Ehlken N, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J. 2012;40(1):84-92. 11. Becker-Gru¨nig T, Klose H, Ehlken N, et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;168(1):375-381. 12. Weinstein AA, Chin LM, Keyser RE, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med. 2013;107(5):778-784. 13. Chan L, Chin LM, Kennedy M, et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest. 2013; 143(2):333-343. 14. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328(24):1732-1739. 15. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114(6):464-469. 16. Galie` N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227-237. 17. Galie` N, Badesch BD, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529-535. 18. Galie` N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117(23):3010-3019. 19. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122-129. 20. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123. 21. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. 22. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353-359. 23. Galie` N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100. 24. Galie` N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48-54. 25. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369(9):809-818. 26. Ghofrani HA, Galie` N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-340. 27. Galie` N, Neuser D, Muller, Scalise AV, Grunig E. A placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). Am J Resp Crit Care Med. 2013;187:A3530. 28. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005;172(1):105-113. 29. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100(2):131-138. 30. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488- 1496.